Synonyms: Klisyri® | KX 2-391 | KX-01 | KX-2-391 | KX2-391
tirbanibulin is an approved drug (FDA (2020), EMA (2021))
Compound class:
Synthetic organic
Comment: Tirbanibulin (KX2-391) is an orally bioavailable small molecule with a dual mode of action. It is a Src kinase inhibitor with potential antiproliferative activity [7-8] and an inhibitor of tubulin polymerization [8].
Synthesis of KX2-391 is described in US patent US20060160800 [2], where it is compound 134. Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Tirbanibulin (KX2-391) was advanced to Phase 3 clinical trial as a potential topically applied treatment for actinic keratoses (see NCT03285490). It has also completed early stage trials in solid and hematological malignancies. The first approval was for use as a treatment for actinic keratosis (of the face or scalp), granted by the FDA in December 2020 [5]. EMA approval for this indication followed in July 2021. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT03285490 | A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp (AK004) | Phase 3 Interventional | Athenex, Inc. |